NCT03745014 is a NA clinical trial of Accelerate Pheno in Gram-negative Bacteremia, sponsored by Accelerate Diagnostics, Inc..

Who is sponsoring NCT03745014?

NCT03745014 is sponsored by Accelerate Diagnostics, Inc..

What drugs are being tested in NCT03745014?

Interventions in NCT03745014: Accelerate Pheno, Standard of Care.

What condition does NCT03745014 study?

NCT03745014 studies Gram-negative Bacteremia.

Is NCT03745014 still recruiting?

NCT03745014 is currently withdrawn. Last updated 14 April 2020.

Last reviewed 2020-04-14 · How we verify

NCT03745014

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Impact of Fast Phenotypic Antimicrobial Susceptibility Testing on Patients With Gram-Negative Rod Bacteremia

Withdrawn NA Last updated 14 April 2020

What this trial tests

NA trial testing Accelerate Pheno in Gram-negative Bacteremia. Withdrawn.

Timeline

30 September 2019

Primary endpoint
30 June 2020

31 August 2020

Quick facts

Lead sponsor	Accelerate Diagnostics, Inc.
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Start date	30 September 2019
Primary completion	30 June 2020
Estimated completion	31 August 2020

Drugs / interventions tested

Accelerate Pheno
Standard of Care

Conditions studied

Gram-negative Bacteremia — all drugs for Gram-negative Bacteremia →

Sponsor

Accelerate Diagnostics, Inc.

Who can join

18 and older, any sex, with Gram-negative Bacteremia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The FDA-cleared Accelerate Pheno™ System and PhenoTest™ Blood Culture (BC) Kit will be used to assess the workflow impact of fast identification (ID)/ antimicrobial susceptibility testing (AST) in the microbiology lab and in the quality of care in patients with Gram-negative rod (GNR) bacteremia. Blood culture work up will be randomized to one of two arms: the positive blood culture will either undergo fast ID and AST using the Accelerate Pheno™ System and PhenoTest™ BC Kit or processing per the site's standard of care (SOC) procedures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection.
Anton-Vazquez V, Hine P, Krishna S, Chaplin M, et al · · 2021 · cited 27× · PMID 34097767 · DOI 10.1002/14651858.cd013235.pub2

Verify or expand the search:

Other recruiting trials for Gram-negative Bacteremia

Currently open trials in the same condition.

NCT06080698 — Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial · NA · recruiting
NCT04291768 — Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia · Phase 4 · recruiting

Other Accelerate Diagnostics, Inc. trials

Trials by the same sponsor.

NCT04295915 — Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03745014 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Accelerate Diagnostics, Inc.
Last refreshed: 14 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03745014.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing